What Are The Projected Market Size And CAGR For The GMP Cell Therapy Consumables Market By The Conclusion Of 2030?
The gmp cell therapy consumables market size has grown exponentially in recent years. It will grow from $22.73 billion in 2025 to $28.79 billion in 2026 at a compound annual growth rate (CAGR) of 26.7%. The growth in the historic period can be attributed to expansion of clinical cell therapy trials, growth of regenerative medicine research, increasing adoption of gmp manufacturing standards, rising investments in cell-based therapies, availability of advanced cell culture tools.
The gmp cell therapy consumables market size is expected to see exponential growth in the next few years. It will grow to $73.96 billion in 2030 at a compound annual growth rate (CAGR) of 26.6%. The growth in the forecast period can be attributed to increasing commercialization of cell therapies, rising demand for scalable gmp production, expansion of gene and immunotherapy pipelines, growing focus on process automation, increasing regulatory scrutiny of cell therapy manufacturing. Major trends in the forecast period include increasing demand for gmp-compliant cell therapy consumables, rising adoption of single-use bioprocessing products, growing use of automated cell processing systems, expansion of standardized cell culture solutions, enhanced focus on quality and regulatory compliance.
Claim Your Free Report Sample Today:
Which Drivers Are Expected To Support The Future Advancement Of The GMP Cell Therapy Consumables Market?
The increasing prevalence of chronic diseases is expected to propel the growth of GMP cell therapy consumables market going forward. Chronic disease refers to a form of illness that lasts for three months or more and can deteriorate with time. Surge in chronic diseases leads to increased research and development in innovative cell therapies to address chronic conditions. The demand for GMP consumables is rising as cell therapy applications expand across various chronic diseases, necessitating quality maintenance in clinical trials. Stringent regulatory compliance and patient demand for innovative therapies further contribute to the market's growth. For instance, in June 2024, according to the National Health Service, a UK-based government department, 3,615,330 individuals registered with a general practitioner (GP) were diagnosed with non-diabetic hyperglycemia or pre-diabetes (a condition with elevated blood sugar levels, not high enough to be classified as diabetes) in 2023, marking an 18% increase from 3,065,825 cases in 2022. Therefore, the increasing prevalence of chronic diseases is driving the growth of the GMP cell therapy consumables market.
Which Segment Categories Are Influencing The Growth Trajectory Of The GMP Cell Therapy Consumables Market?
The gmp cell therapy consumables market covered in this report is segmented –
1) By Product: Kits, Reagents Or Molecular Biology Reagents, Growth Factors Or Cytokines And Interleukins, Other Products
2) By Cell Therapy: NK Cell Therapy, Stem Cell Therapy, T-Cell Therapy
3) By Process: Cell Collection And Characterization Or Sorting And Separation, Cell Culture And Expansion Or Preparation, Cryopreservation, Cell Processing And Formulation, Cell Isolation And Activation
4) By End-Use: Clinical, Commercial
Subsegments:
1) By Kits: Cell Culture Kits, Cell Isolation Kits, Transfection Kits
2) By Reagents Or Molecular Biology Reagents: Buffers And Solutions, Enzymes, Staining Reagents
3) By Growth Factors Or Cytokines And Interleukins: Hematopoietic Growth Factors, Immunomodulatory Cytokines
4) By Other Products: Cell Culture Vessels, Media And Supplements
Which Trends Are Currently Influencing The Direction Of The GMP Cell Therapy Consumables Market?
Major companies operating in the GMP cell therapy consumables market are developing GMP-compliant CD34+ hematopoietic stem cells (HSCs) to support advanced therapies. GMP-compliant CD34+ hematopoietic stem cells (HSCs) refer to a specific type of stem cell that expresses the CD34 marker on its surface and is produced under Good Manufacturing Practice (GMP) conditions. For instance, in April 2024, OrganaBio, a US-based pharmaceutical company, launched HematoPAC-HSC-CB-GMP, an on-demand source of GMP-compliant CD34+ hematopoietic stem cells (HSCs) derived from fresh human cord blood. OrganaBio utilizes its extensive experience in cell isolation and GMP manufacturing to produce high yields of highly viable CD34+ HSCs within 24 hours of collection. This launch aims to facilitate the development of next-generation therapies, including those for blood cancers and genetic disorders.
Which Organizations Are Considered Principal Leaders In The GMP Cell Therapy Consumables Market?
Major companies operating in the gmp cell therapy consumables market are Thermo Fisher Scientific Inc., Merck KGaA, Lonza Group AG, Sartorius AG, Corning Incorporated, Avantor Inc., Fresenius Kabi AG, Miltenyi Biotec, Bio-Techne Corp, STEMCELL Technologies Inc., FUJIFILM Irvine Scientific Inc., BioLife Solutions Inc., PromoCell GmbH, PeproTech Inc., Sino Biological Inc., Wilson Wolf Corporation, Cellexus Ltd., MaxCyte Inc., BioLegend Inc., Repligen Corporation, Terumo Corporation
Get Your In-Depth GMP Cell Therapy Consumables Market Report Now:
Which Regions Are Generating The Highest Demand Within The GMP Cell Therapy Consumables Market?
North America was the largest region in the GMP cell therapy consumables market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gmp cell therapy consumables market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Contact Us:
The Business Research Company: Market Research Reports
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Comments
Post a Comment